TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03112564

Intervention type: OTHER
Group type: OTHER
Intervention: Avoidance of rocuronium/cisatracurium
Description: Anesthesia induction was performed at tidal volume, avoiding the use of analgesics and/or muscle relaxants with FGF of 6 L/min. Induction time was shortened as the FGF was increased. Once 5% sevoflurane end-tidal volume was reached, ventilation with facial mask was maintained for three more minutes. The time lapsed until the loss of blink reflex was achieved and orotracheal tube (OTT) was placed, difficulties in OTT placement, sevoflurane end-tidal volume after OTT placement, complications related to OTT insertion (movement, coughing, rigidity, apnea), mean arterial pressure (MAP) variations were measured. No muscle relaxants were given during surgery.

Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane 8% + Intravenous fentanyl
Description: Sevoflurane 8% + Intravenous fentanyl was the regimen used for induction and maintenance of anesthesia
Study: NCT02058654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Creatine powder (5 g)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bulking agent powder (5 g)
Study: NCT01386073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FreshKote
Description: Three times a day for three months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Systane
Description: three times a day for three months
Study: NCT01586637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: This group performed dance classes and regarding the art therapy they have art classes where they learn how to use the drawing to express feelings. The classes were twice a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Description: The group walked twice a week during one hour.
Study: NCT01465347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate (TSC)
Description: TSC administered intravenously as a bolus injection prior to radiation therapy sessions during 6 weeks of radiotherapy.
Study: NCT00687973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan/amlodipine 80/5 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 10 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol 50 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol 100 mg tablets
Study: NCT00906945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Study: NCT03580811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental implant & ADMG & BDX
Description: Dental Implant will be placed with ADMG that covers the BDX
Study: NCT00906945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study: NCT02020759

Intervention type: DEVICE
Intervention: Transcranial Doppler Ultrasound
Description: Transcranial Doppler Ultrasound is used to monitor cerebral microembolism

Intervention type: DEVICE
Intervention: Transcranial Doppler Ultrasound
Description: Transcranial Doppler Ultrasound is used to monitor cerebral microembolism

Intervention type: DEVICE
Intervention: Transcranial Doppler Ultrasound
Description: Transcranial Doppler Ultrasound is used to monitor cerebral microembolism
Study: NCT01111747

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Intra-operative use of platelet-rich plasma in the patellar tendon after harvesting its central third for ACL reconstruction.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: In this group PRP will not be added to the patellar tendon donor site at the end of ACL reconstruction.
Study: NCT02481947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI400 Laxative
Description: 21 gm BLI400 powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone
Description: 24 mcg capsule bid
Study: NCT02519400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Single oral dosing
Study: NCT02224976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensified Training
Description: Volunteers will increase exercise training by 30% from baseline
Study: NCT03994289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor-assisted cycling
Description: Participants will perform the motor-assisted cycling exercise using a physical therapy bike (RECK; Betzenweiler, Germany). Participants will perform 3×10-min bouts of motor-assisted cycling at the highest tolerable cadence. Before each bout, participants will perform 1-2 minutes of motor-assisted cycling at 5-10 rpm as a warm-up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FES cycling
Description: The testing procedures will be identical to that in the motor-assisted cycling visit except for the exercise type. Participants will wear FES cuffs on the upper and lower legs, bilaterally.~. The FES cycling will be performed on the motor-assisted bike using the wearable FES equipment. The purpose of motor-assisted cycling is to provide constant cadence. The Bioness L300 Plus system (Bioness, Valencia, CA) will be worn on the upper and lower legs to stimulates the quadriceps and dorsiflexors muscles during the motor-driven cycling exercise. An embedded gyroscope of the cuff can detect the motion of the lower leg so that the electrical stimulations will be generated at appropriate timing to activate leg muscles during the cycling exercise.
Study: NCT02121834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3050258

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY3050258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03389906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gold
Description: Approximately 72000, 20-40 my-meter diameter, sterilised gold particles (=20 mg) will be provided in vials (The Berlock® Gold Implants). 5-10 ml of synovial fluid is aspirated (20G needle) from most affected OA-knee. The vial of gold particles are mixed with the synovial fluid, and the mix of gold and synovial fluid is injected intra-articularly into the patients knee.
Study: NCT03407560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SintLife
Description: Patients will be treated for degenerative diseases of the spine, such as lumbar stenosis, spondylolysis and spondylolisthesis, degenerative disc disease.~The fusion technique used will be the posterolateral arthrodesis of one or more vertebral levels included in the lumbosacral region (L1-S1), obtained by screws and bars, together with a preparation of the transverse processes treated with bone substitute in order to Sintlife obtain new bone formation and then spinal fusion. It is also possible to associate interbody fusion with the use of a cage.
Study: NCT00648154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole Tablets 2.5 mg
Description: 2.5mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femara® Tablets 2.5 mg
Description: 2.5mg, single dose fed
Study: NCT01515397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gelofusine balanced
Description: Gelofusine balanced combined with Sterofundin ISO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gelofusine 4%
Description: Gelofusine 4% combined with NaCl 0.9%
Study: NCT02968082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Patch will be applied under the ear of the opposite side of operation, at 9 p.m. of the day before the operation day. Nausea will be assessed by Visual Analogue Scale (VAS) immediate after arrival at a recovery room and the ward. After that, nausea will be continuously assessed every 4 hour (4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after surgery) and a number of vomiting will also be counted. Basic clinical characteristics and the number of antiemetic administration will be identified through medical records.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patch will be applied under the ear of the opposite side of operation, at 9 p.m. of the day before the operation day. Nausea will be assessed by Visual Analogue Scale (VAS) immediate after arrival at a recovery room and the ward. After that, nausea will be continuously assessed every 4 hour (4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after surgery) and a number of vomiting will also be counted. Basic clinical characteristics and the number of antiemetic administration will be identified through medical records.
Study: NCT03814187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran Sodium
Description: Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
Study: NCT03286257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: A partially supervised 16-week moderate intensity exercise intervention consisting of 3-5 sessions per week.
Study: NCT02666846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methyl-salicylate / Menthol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04260880

Intervention type: OTHER
Intervention: periodontal status in mild depression patients
Description: Assessment of periodontal status in mild depression patients

Intervention type: OTHER
Intervention: periodontal status in moderate depression patients
Description: Assessment of periodontal status in moderate depression patients

Intervention type: OTHER
Intervention: periodontal status in systemically healthy patients
Description: Assessment of periodontal status in systemically healthy patients
Study: NCT02628496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein injection, USP 10%
Description: -2.5 ml intravenous 10 minutes before procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confocal laser microlaryngoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy (standard of care)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: KTP laser photoablation (standard of care)
Study: NCT00904605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidoderm
Description: Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
Study: NCT03027609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-105
Description: monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo (+ SOC antibiotics)
Study: NCT01197118

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: sequence chemoradiotherapy
Description: Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 15MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative chemotherapy regimen: see arm 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy alone following radical resection
Description: Postoperative chemotherapy regimen: The OLF regimen was administrated: Oxaliplatin, 130 mg/m2/day on day1, i.v. 2 h; fluorouracil, 425 mg/m2/day on day1\~5, i.v.; leucovorin, 200 mg/m2/day on day 1\~5, i.v.; every 21 days repeated, for 6 cycles.
Study: NCT04830332

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: abdominal fluid CA-125 levels test
Description: One hundred milliliters of normal saline was used as the abdominal washing liquid to obtain the sample for CA-125 measurement. Serum and abdominal washing fluid CA-125 levels were measured with a double antibody sandwich immunoenzymatic method, using Beckman Coulter DXI (Ireland) analyzer. I
Study: NCT01595542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Vaccine Consent Form
Description: Packet of written immunization materials for parents and students which includes the following:~1. Cover letter~2. Vaccine promotional flyer~3. Vaccine information sheets (one for adolescent vaccination and one for other vaccination)~4. Improved consent form~5. Note advertising a lottery for free movie tickets for returning the consent form~6. Self-addressed stamped envelope
Study: NCT01049022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Single intravenous (IV) infusion of moxifloxacin administered over 60 minutes, at an initial dosage of 5 milligram per kilogram per body weight (mg/kg/BW) with dose escalation to 6 mg/kg in subjects of age 6 years (yrs) to less than or equal to (\<=) 14 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 7 mg/kg/BW with dose escalation to 8 mg/kg in subjects of age 2 years to less than (\<) 6 years; dose escalation was based on evaluations of the pharmacokinetic (PK) and safety data from the subjects in a preceding cohort.
Study: NCT00948051

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Follow-on formula supplemented with fructo-oligosaccharides
Description: Follow-on formula supplemented with fructo-oligosaccharides
Study: NCT01049022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 9 mg/kg/BW with dose escalation to 10 mg/kg in subjects of age 3 months to \< 2 years; dose escalation was based on evaluations of the PK and safety data from the subjects in a preceding cohort.
Study: NCT04689607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Traction Straight Leg Raise (TSLR)
Description: The patient was in a supine position on a low bed and the therapist faced the limb of the patient that was to be treated. The therapist grasped the lower leg of the patient just near the ankle and raises the leg off the bed to a position just above the painful range. The therapist flexes the knees. Traction was retained as far as possible with a straight leg lift if there was no pain. The pain-free traction straight leg raise range was administered for 10 second and the procedure was repeated three times.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post Isometric Relaxation technique (PIR):
Description: The knee of the affected leg was extended, and the affected hip was flexed. Then the calf of the patient was placed on the shoulder of therapist. The therapist was standing on the side of the affected leg. The flexion of the hip was performed on the affected leg until resistance was felt. The patient was asked to gently push down on the therapist's shoulder with the leg. The therapist resisted hip extension to create an isometric contraction. The duration of the contraction was 10 seconds. Then the patient was instructed to relax and the therapist gently flexed the hip until the next barrier was felt. The technique was repeated three times.
Study: NCT04611646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heat-suit endurance training
Description: Participants (elite cyclists) will conduct five 50-minute low-intensity cycling sessions with heat suit per week for five weeks. These sessions will complement their habitual training routines, which will consist of endurance training with intensities at or below lactate threshold. Participants will ingest 100 mg Fe2+ on a daily basis to support de novo synthesis of hemoglobin
Study: NCT00948051

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Follow-on formula enriched with placebo (maltodextrins)
Description: Follow-on formula enriched with placebo (maltodextrins)
Study: NCT03946150

Intervention type: DIAGNOSTIC_TEST
Intervention: P/FP Ratio
Description: PaO2/Fio2 X PEEP
Study: NCT04611646

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Non-heat-suit endurance training
Description: Participants (elite cyclists) will conduct low-intensity cycling without heat suit for five weeks (volume- and intensity-matched to the heat-suit arm). Participants will ingest 100 mg Fe2+ on a daily basis to support de novo synthesis of hemoglobin
Study: NCT01815918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Patients randomized to treatment arm will three doses of 100 mg of hydrocortisone at the following times: prior to surgery, 8 hours after the first dose and 16 hours after the first dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive placebo prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
Study: NCT03877510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX203
Description: IPX203 extended release capsules
Study: NCT02526147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voucher

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Study: NCT02690922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 100mg (d1-d84)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 60mg/m2 d1-24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 10mg/d 3-7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 3g/m2 1day
Study: NCT01762891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: celecoxib 200mg/day by oral rout during 15 days followed by the administration of rofecoxib 25mg/day, acetaminophen 3g/day and placebo during 15 days each drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 3g/ was given during 15 days by oral rout following one of the other interventions or as the final intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Description: Rofecoxib 25mg/day was given by oral rout during 15 days following one or more interventions or as the final intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo pills were given during 15 days by oral rout as one of the four interventions.
Study: NCT04097392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Diaphragm biofeedback reeducation plus inspiratory training during 6 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Isolated high-intensity inspiratory muscle training during 8 weeks